NCT03448081 - Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

November 21, 2018

Study Completion Date

December 10, 2018

Conditions

PruritusPsoriasis

Interventions

DRUG

SNA-120

SNA-120 (0.5%) active ointment

DRUG

Placebo

Vehicle Ointment

DRUG

Calcipotriene

Calcipotriene ointment (0.005%)

Trial Locations (20)

14623

Sienna 020, Rochester

27612

Site 014, Raleigh

32771

Site 015, Sanford

33143

Site 013, Coral Gables

36207

Sienna 018, Anniston

36608

Sienna 009, Mobile

46256

Site 012, Indianapolis

48088

Sienna 011, Warren

73118

Sienna 002, Oklahoma City

77004

Sienna 010, Houston

78213

Sienna 001, San Antonio

78660

Sienna 021, Pflugerville

78745

Sienna 017, Austin

90045

Sienna 007, Los Angeles

91403

Site 016, Sherman Oaks

92708

Sienna 019, Fountain Valley

08009

Sienna 005, Berlin

V3R 6A7

Sienna 006, Surrey

K9J 5K2

Sienna 008, Peterborough

H2K 4L5

Sienna 003, Montreal